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aBstraCt
Vitreomacular traction is a common phenomenon causing a decrease in visual acuity, metamorphopsia, and disorders 
of central vision. The introduction of intravitreal ocriplasmin injection provided a new possibility of noninvasive 
treatment of this syndrome. The novelty of this case is that the ocriplasmin is a new treatment possibility and its 
combination with ranibizumab treatment has rarely been reported. The aim was to report a case of an 83-year-old 
man treated with intravitreal ocriplasmin and ranibizumab injections because of coexisting vitreomacular traction 
and exudative age-related macular degeneration.
A patient was referred to our clinic due to complaints about progressive central visual acuity decrease and metamor-
phopsia in the right eye observed within the last year. Before intravitreal 125-µg ocriplasmin injection the patient 
underwent ophthalmic examinations including best corrected visual acuity, slit-lamp, and fundoscopy and optical 
coherence tomography. After diagnosing with exudative age-related macular degeneration the patient was referred to 
three loading doses of anti-VEGF therapy. Three weeks after ocriplasmin injection the patient’s best corrected visual 
acuity improved. Ophthalmic examinations revealed the occurrence of exudative age-related macular degeneration. 
After three loading doses of anti-VEGF therapy ophthalmic examinations disclosed vitreomacular traction release 
and retinal fluid absorption.
Coexistence of vitreomacular diseases may be the reason for poor response to anti-VEGF treatment in patients with 
exudative age-related macular degeneration. Simultaneously, pharmacological vitreolysis using ocriplasmin injection 
may be an effective and safe method of vitreomacular traction treatment.
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introduCtion
Ageing changes occur in all structures of the eye. 
Common phenomenon frequently related to aging 
of ocular structures is posterior vitreous detachment 
(PVD). As we age, the vitreous gel liquefies and 
contracts away from its posterior adhesion at the 
retina, optic disk, and retinal vessels. Studies have 
showed that the posterior vitreous detachment is 
detected in half of 50-year-old subjects and almost 
in all subjects aged 80 years or older [1].
Incomplete posterior vitreous detachment may 
cause vitreomacular traction (VMT). This frequent 
macular condition causes anatomical changes in the 
contour of the foveal surface, intraretinal pseudocyst 
formation, and disappearance of foveal depression, 
which results in reduced or distorted vision [2–3].
The prevalence of vitreomacular traction has 
been estimated as approximately 22.5 cases per 
100,000 of the general population, with an inci-
dence of 0.6/100,000 persons-year [4].
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Development of non-invasive high-resolution 
optical coherence tomography (OCT) imaging has 
provided new insight into the understanding of vitr-
eomacular traction syndrome by providing better 
evaluation of the tractional forces at the vitreoretinal 
interface, as well as recognising its relationship with 
particular macular conditions. 
Nowadays, VMT is believed to be associated 
with a broad spectrum of maculopathies, including 
cystoid macular oedema (CMO), epiretinal mem-
brane (ERM), and macular hole (MH) formation, 
all attributed to a common aetiology [5–6]. 
Krebs and Schulze suggested that vitreoretinal 
interface abnormalities, specifically vitreomacular 
traction, may be a potential risk factor in the de-
velopment of exudative age-related macular degen-
eration (eAMD) [7–9]. The current standard care 
for neovascular age-related macular degeneration is 
anti-VEGF therapy through anti-VEGF injections. 
We would like to present a  case of VMT ac-
companied by eAMD and a novel approach to the 
treatment of coexistence of these diseases. Ocriplas-
min is not the only innovative therapeutic agent. 
Also, very rarely clinicians decide to use both agents 
simultaneously. The presented case confirmed the 
effectivity of combining two therapies.
MateriaLs, Methods, and resuLts
An 83-year-old man was referred to our clinic 
due to complaints about progressive central visual 
acuity decrease and metamorphopsia in the right 
eye observed within the last year. The previous med-
ical history was unremarkable except for hyperten-
sion and cataract extraction using phacoemulsifi-
cation with intraocular lens implantation in the 
left eye. After the treatment the patient’s best cor-
rected visual acuity (BCVA) increased from 0.3 to 
0.7. The right eye had not been subjected to any 
treatment previously.
At the initial visit, the BCVA was 0.2 in the right 
eye and 0.7 in the left eye. Ophthalmological ex-
amination using slit-lamp and fundoscopy revealed 
cortico-nuclear cataract, vitreous condensation in 
the macula region and multiple drusen in the right 
eye (Fig. 1A). The left eye was pseudophakic, with 
posterior capsule opacity. The fundoscopy view sug-
gested macular hole.
Spectral-Domain OCT demonstrated foveal 
vitreomacular traction with marked cystic distortion 
of the central retina in the right eye and hypore-
flective space under neurosensory retina — eAMD 
suspicion (Fig. 1B). Lamellar macular hole with 
total posterior vitreous detachment and confluent 
hard drusen were detected in the left eye.
B-scan ultrasound of right eye revealed partial 
PVD with focal VMT attached to the region of 
the macula.
The patient was qualified for intravitreal in-
jection of 125 µg ocriplasmin (Jetrea®; Thrombo-
Genics, Iselin, N.J., USA) to the right eye. Before 
ocriplasmin treatment the patient gave formal writ-
ten consent. The patient’s treatment was part of 
a  study approved by the Bioethical Committee of 
the Medical University of Silesia (approval number 
KNW/0022/KB1/13/I/15) and was conducted in 
accordance with the Declaration of Helsinki. It was 
assumed that the treatment would allow to stabilisa-
tion or improvement of patient’s vision. Moreover, 
it was predicted that the applied treatment would 
prevent further destruction of the retina resulting 
from VMT mechanical pull on the retina as well as 
the unfavourable impact of neovascular age-related 
macular degeneration. 
Figure 1. Fundoscopy of right eye. Vitreous condensation in macula region and drusen (a); Right eye. OCT scan before ocriplasmin injec-
tion. Focal vitreomacular traction with intraretinal cysts. Retinal distortion caused by abnormal traction forces on macula by the posterior 
vitreous face. Hyporeflective space under the neurosensitive retina — eAMD suspicion (B)
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Three weeks after this injection the BCVA in 
his right eye improved to 0.4. Follow-up OCT still 
showed VMT with less intensity of the traction in 
the fovea region with smaller cystic spaces. Addi-
tionally, subretinal fluid and focal hyperreflective 
space in the retina was shown. The scans suggest-
ed intercurrent active choroidal neovascularisation 
(CNV) — exudative age-related macular degener-
ation (eAMD) (Fig. 2A). Fluorescein angiography 
confirmed CNV — exudative age-related macular 
degeneration (Fig. 2B).
Due to diagnosis of eAMD the patient was re-
ferred for three loading doses of anti-VEGF therapy. 
One week later the patient underwent a first intra-
vitreal injection of 0.5 mg ranibizumab (Lucentis; 
Novartis, Basel, Switzerland, and Genentech, Inc., 
South San Francisco, Calif., USA). At a follow-up 
visit four weeks later the BCVA was 0.4. OCT re-
vealed a decrease in subretinal fluid. Residual VMT 
was still observed. Three days later a second dose of 
ranibizumab was injected into the right eye. 
One week after the second injection of ranibi-
zumab, the best corrected visual acuity of the right 
eye improved to 0.5. OCT showed complete VMT 
release. Subretinal fluid was not detected in the 
treated eye (Fig. 2C). Three weeks later the patient 
underwent a  third loading ranibizumab injection. 
In the control examination OCT scans were stable 
— there was no fluid under neurosensory retina. 
BCVA improved to 0.7.
During the treatment no adverse events were ob-
served. The treatment was well tolerated by the pa-
tient.
It should be emphasised that the patient ex-
pressed high satisfaction with the therapy results, 
connected with visual acuity improvement and 
overcoming troubling symptoms in the form of 
metamorphopsia and micro- and macropsia.
It is believed that the novelty and effectiveness 
of the applied treatment method are undoubted 
strengths of the approach to this case. Moreover, an 
advantage is the individualisation of the approach.
disCussion
VMT was first described and confirmed by his-
tological studies in 1970 by Reese et al. [10].
Development of noninvasive OCT imaging in 
the last two decades has provided new insight into 
VMT — our understanding of the pathophysiology 
of this condition and its role in the pathogenesis of 
other symptoms of the retina.
Figure 2. RE OCT scan 3 weeks after ocriplasmin injection. 
Dissolving vitreomacular traction with foveal cystoids changes 
involving the inner retina. Subretinal fluid (a); RE FA. An area 
of hyperfluorescence identified in the early phase of angiogram, 
which progressively intensifies throughout the transient phase, 
with leakage of dye (B); RE OCT scan. One week after second 
ranibizumab injection. Vitreomacular traction release. Absence of 
subretinal fluid (C)
Typical symptoms reported by patients with 
vitreomacular traction are: decrease of visual acu-
ity, metamorphopsia, and disorders of central vi-
sion [5].
Until now, treatment of symptomatic vitreomac-
ular traction causing the decrease of visual acuity 
and the disrupting layer structure of the retina was 
the pars plana vitrectomy procedure, which is bur-
dened with the risk of severe intraoperative complica-
tions. Clinicians made the decision to carry our pars 
plana vitrectomy when visual acuity was below 5/16.
The introduction of intravitreal ocriplasmin in-
jection provided a  new possibility of noninvasive 
treatment [11].
Ocriplasmin is a truncated form of human plas-
min produced by DNA recombination methods. It 
is characterised by strong proteolytic activity to-
a
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wards vitreous body protein and the connection 
between the vitreous body and the retina.
Through lamin and fibronectin digestion, colla-
gen leads to enzymatic vitreolysis — dissolution of 
protein matrix, which is the cause of the abnormal 
adhesion of the vitreous body to the retina [12–15].
In phase III of the MIVI-TRUST trials Stels-
mans et al. proved that in comparison to placebo, 
ocriplasmin application (in a  dose of 125 µg, in 
a  volume of 0.1 mL) in adults with symptomatic 
vitreomacular traction, after 28 days observation 
period, increased the probability of vitreomacular 
adhesion (VMA) detachment and macular hole 
closure without the need of surgical intervention. 
Pharmacological VMT detachment was observed 
in 26.5% of eyes after ocriplasmin injection in com-
parison to 10.1% of eyes after placebo (p < 0.001). 
Full posterior vitreous detachment was more fre-
quent in eyes treated with ocriplasmin (13.4%) than 
in eyes treated with placebo (3.7%). Nonsurgical 
closure of macular hole was observed in 40.6% 
of eyes after ocriplasmin injection as compared to 
10.6% of eyes after placebo injection [16].
Simultaneously, after ocriplasmin injection float-
ers may occur in the vitreous body. Moreover, the 
injection increased the probability of complications 
in the form of photopsia, conjunctival bleeding, eye 
pain caused by injection, blurred vision and vision 
disturbances without increasing the risk of severe 
complications including macular hole formation, 
retinal detachment, and visual acuity decrease [16].
At the Cole Clinic 33% (8/17) of patients 
achieved VMA resolution, and 80% (4/5) had clo-
sure of their full thickness macular hole (FTMH) 
after ocriplasmin injection [17].
Krebs and Schulze suggested that vitreoretinal 
interface abnormalities, specifically vitreomacular 
traction, may be a potential risk factor in the de-
velopment of exudative age-related macular de-
generation [7–9]. In the literature we can find 
numerous hypotheses trying to explain how the 
diseases of vitreoretinal junction influence neo-
vascularisation development. The most common 
cause mentioned in the literature is induced se-
cretion of proangiogenic factors (VEGF) in the 
course of these diseases [18–19]. The mechanical 
distortion of RPE caused by forces affecting the 
retina in the course of VMT may stimulate the 
retinal pigment epithelium to secrete VEGFs as 
a response to mechanical stress [20–21].
Additionally, it is believed that vitreous body de-
tachment is associated with better retinal oxidation, 
and that adhered vitreous body decreases it. Retinal 
hypoxia is a well-known potential factor stimulating 
the secretion of vascular growth factors [22].
This may explain worse response to anti-VEGF 
treatment in patients with neovascular AMD and 
comorbid diseases of vitreoretinal space.
ConCLusions
The reason for poor response to anti-VEGF 
treatment in patients with neovascular AMD might 
be coexisting pathologies of vitreoretinal junc-
tions. An effective and safe method of symptomatic 
vitreomacular traction treatment is pharmacological 
vitreolysis with the use of intravitreal ocriplasmin 
injection. It is also an excellent example of the pre-
vailing trend in modern ophthalmology — mini-
mising the invasiveness of medical procedures. 
Favourable examination outcomes after the 
treatment confirmed the legitimacy of ocriplas-
min and ranibizumab application in patients with 
coexisting vitreomacular traction and neovascular 
age-related macular degeneration. 
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